NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Comments to OTR on CBP interpretive rule regarding on 19 U.S.C. 1304 and 19 C.F.R. Part 134 titled "Pharmacy Concerns Regarding U.S. Customs and Border Protection Ruling on Prescription Marking for Country of Origin (COO)";
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| STEVEN W POSTAL | — |
Alcohol and Drug Abuse ALC
S. 2666, the E-Prescribing Parity for Controlled Substances Act; Remote Prescribing of Controlled Substances & Dispensing of Controlled Substances; H.R. 9886/S.5271, the BUPE for Recovery Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Medicare/Medicaid MMM
H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment to CMS on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027."; H.R. 9096, the Pharmacists Fight Back Act; Long Term Care at Home Pharmacy Services in Medicare; Regulating fair and common-sense contracting guardrails between Part D plans/PBMs, and pharmacies; Comments to CMS on Proposed Rule Re: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments [CMS-1807-P]; H.R.4758, the Accelerating Kids Access to Care Act; H.R. 8107, the Ensuring Access to Medicaid Buy-in Programs Act of 2024; Comments to CMS on Draft Guidance Re: Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027; Request for Information to CMS on "Medicare $2 Drug list Model" (Executive Order 14087 of October 14, 2022); H.R.5074/S.5410, the Kidney PATIENT Act; H.R.4104/S.1976, the Preserving Patient Access to Home Infusion Act; H.R.10545, the American Relief Act, 2025;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Pharmacy PHA
H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542 / H.R. 6283, the Delinking Revenue from Unfair Gouging Act; H.R. 1173, the Patients Right to Know Their Medication Act of 2023; Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959); Implementation of Public Law 113-54, the Drug Quality and Security Act; Draft Guidance for Industry, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, (Docket No. FDA-2015-D-3517); H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act" (Docket No. FDA-2023-N-4806); Request for Information on Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024; H.R.2882, the Further Consolidated Appropriations Act, 2024; Comments on implementation and enforcement of recent changes to USP Chapter <797>, regarding the Compounded Sterile Preparations (CSPs) in Category 3 to the FDA; Comments to FDA on "Agency Information Collection Activities; Proposed Collection; Comment Request; Proposed Small Dispensers Assessment Under the Drug Supply Chain Security Act" [Docket No.FDA-2024-N-0668]; Comments to FDA on " Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act"[Docket No. FDA-2023-N-0061]; H.R.9096, the Pharmacists Fight Back Act; Comments to FDA on Docket No. FDA-2023-N-4806 - Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket; Request for Information and Comment. Comments to FDA on "Pharmacy Compounding Advisory Committee's Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List Revisions to the Withdrawn or Removed List [Docket No. FDA-2024-N-4188]"; Comment to FDA on "Pharmaceutical Distribution Supply Chain; Drug Supply Chain Security" [Docket No. FDA-2024-N-3675]; Comment to FDA on "Opposition to Novo Nordisk and Eli Lillys Requests to Place GLP-1 Medications on the Demonstrably Difficult to Compound List" [Docket No. FDA-2015-N-0030]; H.R.10239/S.5368,the Ending Drug Shortages Act; H.R.10362, the PBM Act of 2024; H.R.10545, the American Relief Act, 2025;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Taxation/Internal Revenue Code TAX
H.R. 4794, the Dietary Supplement Access Act; H.R.8147, Repealing Big Brother Overreach Act; H.R. 9278, To amend section 5336 of title 31, United States Code, to provide existing small businesses with an additional year to file beneficial ownership information, and for other purposes;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Labor Issues/Antitrust/Workplace LBR
S. 127, the PBM Transparency Act; S. 113, the Prescription Pricing for the People Act; Request for Information on "Consolidation in Health Care Markets [Docket No. ATR 102]"; H.R.10362, the PBM Act of 2024;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Defense DEF
TRICARE pharmacy network changes; H.R. 2670, National Defense Authorization Act for Fiscal Year 2024; H.R. 4638, National Defense Authorization Act for Fiscal Year 2025; S.4638, National Defense Authorization Act for Fiscal Year 2025;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Budget/Appropriations BUD
FY24 appropriations language request to fund FTC enforcement of the Robinson-Patman Act; FY24 appropriations report language to address TRICARE pharmacy network; Labor, Health and Human Services, Education, and Related Agencies Appropriations Bill, FY 2025;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Telecommunications TEC
Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.